A missed opportunity
02/05/24 -"CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and well-prioritised R&D pipeline. Investors may ..."
Pages
52
Language
English
Published on
02/05/24
You may also be interested by these reports :
23/05/24
CureVac has released its Q1 figures, which unexpectedly show a significant cash drain due to raw material commitments. However, one positive note is ...
23/05/24
2023 earnings exceeded the street’s expectations and Faes is also off to a good start in 2024. In the near-to-medium term, growth should be driven by ...
21/05/24
Jean-Paul Clozel to step down as CEO
20/05/24
BioNTech (Buy, Germany) is a beacon among the much-battered German biotechnology cohort. Founded with venture capital in 2008, the company sits on a ...